Endpoints News 生物医药· ENDPOINTS·· 7 天前AI 评分45
Regeneron 公布 POTS 中期数据;Kyverna 提交 CAR-T 申请
Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filing
AI 导读
Regeneron 的单克隆抗体 baloncibart 在 POTS 中期试验中剂量为 450 mg。Kyverna 已完成 CAR-T 细胞疗法的监管申报。
正文
Plus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis.
Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news